NYSE · Biotech stocks database
IQV (IQVIA Holdings Inc.) stock: $266.42, $43.85B market cap, $1.91B cash, $55.93B EV, $47.83B fully diluted market cap. Next expected readout: Feb-27. Data from Fully Diluted's biotech stocks database.
| Cash | $1,909.0M |
|---|---|
| Debt | $13,989.0M |
| Net cash | -$12,080.0M |
| Enterprise value | $55,932.7M |
| Basic shares | 164.6M shares |
| Fully diluted shares | 179.5M shares |
| Fully diluted market cap | $47,833.4M |
| Cash per share | $11.60 |
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Loading IQV daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Feb 6 - Mar 20 | Oregovomab | Phase 3 | Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer | — |
| Mar 13 - Apr 24 | Ixovex-1 | Phase 2 | Solid Tumor; Head and Neck Cancer | — |
| Jul 13 - Aug 24 | Acellular Tissue Engineered Vessel (ATEV) | Phase 3 | End Stage Renal Disease (ESRD) | — |
| Apr 12 - May 24 | J147 Emulsion for Injection | Phase 2 | Acute Ischemic Stroke | — |
| Jul 13 - Aug 24 | Olorofim | Phase 2 | Coccidioidomycosis; Disseminated Fungal Infection; Coccidioides Infection | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.